TY - JOUR
T1 - Carvedilol update III
T2 - Rationale for use in congestive heart failure
AU - Feuerstein, G. Z.
AU - Poste, G.
AU - Ruffolo, R. R.
PY - 1995
Y1 - 1995
N2 - In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for ethical reasons due to the remarkable reduction in mortality observed in patients receiving carvedilol plus conventional therapy (i.e., angiotensin converting enzyme inhibitors, diuretics and digitalis) compared to patients receiving placebo plus conventional therapy. The dramatic reduction in mortality produced by carvedilol occurred across all studies and was observed in patients with mild, moderate and severe heart failure. The results of these dramatic clinical trials with carvedilol will be presented later this year.
AB - In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for ethical reasons due to the remarkable reduction in mortality observed in patients receiving carvedilol plus conventional therapy (i.e., angiotensin converting enzyme inhibitors, diuretics and digitalis) compared to patients receiving placebo plus conventional therapy. The dramatic reduction in mortality produced by carvedilol occurred across all studies and was observed in patients with mild, moderate and severe heart failure. The results of these dramatic clinical trials with carvedilol will be presented later this year.
UR - http://www.scopus.com/inward/record.url?scp=0029145195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029145195&partnerID=8YFLogxK
U2 - 10.1358/dot.1995.31.5.325339
DO - 10.1358/dot.1995.31.5.325339
M3 - Review article
AN - SCOPUS:0029145195
SN - 1699-3993
VL - 31
SP - 307
EP - 326
JO - Drugs of Today
JF - Drugs of Today
IS - 5
ER -